Enfortumab vedotin

Generic name: Enfortumab Vedotin
Brand names: Padcev
Dosage form: intravenous powder for injection (ejfv 20 mg; ejfv 30 mg)
Drug class: Miscellaneous antineoplastics

Usage of Enfortumab vedotin

Enfortumab vedotin is used to treat cancer of the bladder or urinary tract that has spread to other parts of the body (metastatic), or cannot be removed with surgery.

Enfortumab vedotin is usually given after other treatments such as immunotherapy and platinum cancer medicine, or if you are unable to receive platinum cancer medicine.

Enfortumab vedotin may also be used for purposes not listed in this medication guide.

Enfortumab vedotin side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

enfortumab vedotin can cause a severe or life-threatening skin rash. Get emergency medical help if you have a worsening rash with itching, blistering, peeling, skin lesions that look like rings, a fever or flu-like symptoms, swollen glands, or painful sores in your mouth, nose, throat, or genital area.

Call your doctor at once if you have symptoms of high blood sugar:

  • increased thirst, dry mouth, fruity breath odor;
  • increased urination;
  • blurred vision, confusion, drowsiness; or
  • nausea, vomiting, stomach pain, loss of appetite.

    • Also call your doctor at once if you have:

  • numbness, tingling, or muscle weakness in your hands or feet;
  • new or worsening cough, trouble breathing, or shortness of breath;
  • pain, redness, and peeling skin on your hands or feet;
  • severely dry eyes, vision problems;
  • redness, itching, swelling, or discomfort where the medicine was injected; or
  • low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath.

    • Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

    Common side effects of enfortumab vedotin may include:

  • high blood sugar;
  • numbness or tingling;
  • muscle weakness;
  • low blood cell counts;
  • feeling tired;
  • nausea, diarrhea;
  • loss of appetite, weight loss;
  • rash, dry skin, itching;
  • changes in your sense of taste;
  • hair loss; or
  • abnormal blood tests.

    • This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Before taking Enfortumab vedotin

    Tell your doctor if you have ever had:

  • numbness or tingling in your hands or feet;
  • diabetes;
  • high blood sugar;
  • liver disease.

    • Enfortumab vedotin can harm an unborn baby if the mother or the father is using enfortumab vedotin.

  • If you are a woman, you may need a pregnancy test to make sure you are not pregnant. Use birth control while using this medicine and for at least 2 months after your last dose.
  • If you are a man, use birth control if your sex partner is able to get pregnant. Keep using birth control for at least 4 months after your last dose.
  • It may be harder for you to get a woman pregnant while you are using this medicine. You should still use birth control to prevent pregnancy because the medicine can harm an unborn baby.
  • Tell your doctor right away if a pregnancy occurs.

    • Do not breastfeed while using this medicine, and for at least 3 weeks after your last dose.

    Relate drugs

    How to use Enfortumab vedotin

    Usual Adult Dose for Urothelial Carcinoma:

    1.25 mg/kg (up to a maximum of 125 mg for patients weighing 100 kg or greater) IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycleDuration: Until disease progression or unacceptable toxicity.Comment:-Combination therapy with Pembrolizumab is approved under accelerated approval based on tumor response rate and durability of response.Use: For the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who: -have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy-are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapyIn combination with pembrolizumab, for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy

    Warnings

    This medicine can cause a severe or life-threatening skin rash. Get emergency medical help if you have a worsening rash with itching, blistering, peeling, skin lesions that look like rings, a fever or flu-like symptoms, swollen glands, or painful sores in your mouth, nose, throat, or genital area.

    What other drugs will affect Enfortumab vedotin

    Many drugs can affect your blood levels of enfortumab vedotin, which may increase side effects. Tell your doctor about all your other medicines, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords